Top Markets
#1 Siren Siren +38.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.79%
#3 RedStone RedStone +18.90%
#4 Verus Coin Verus Coin +18.06%
#5 Ocean Protocol Ocean Protocol +15.61%
#6 Cysic Cysic +15.47%
#7 OpenEden OpenEden +14.56%
#8 Perle Perle +12.68%
#9 KUB Coin KUB Coin +12.53%
#10 Arowana Arowana +11.84%
Coin of the day
Siren Siren
Settings
Language
ENGLISH
Currency
USD
Theme
AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc.

ACRX
Rank in Stocks #31915
AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily... AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.
Share Price
$0.922
Last synced: 2024-02-05
Market Cap
$11.68M
Change (1 day)
-1.91%
Change (1 year)
0.00%
Country
US
Trade AcelRx Pharmaceuticals, Inc. (ACRX)

Category

Healthcare
Earnings for AcelRx Pharmaceuticals, Inc. (ACRX)
Earnings in 2026 TTM: 0
According to AcelRx Pharmaceuticals, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AcelRx Pharmaceuticals, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
- -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
- -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
- -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
- -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
$1.76B -
IN